Blasé biotech stocks met the last weekend of the year with regulatory news, and not much else. Mylan(MYL Quote) said Friday that it received approval from the U.S. Food and Drug Administration for its generic over the counter (OTC) version of Pfizer's zyrtec, or cetirizine hydrochloride tablets. Pfizer's Zyrtec harnessed U.S. sales of approximately $1.4 billion for the year ended Sept. 30.
Mylan's shares rose 19 cents, or 1.4%, to $13.99.
Perrigo(PRGO Quote) also announced that it has received final FDA approval for its Abbreviated New Drug Application (ANDA) for OTC generic Zyrtec. Its shares were trading down 29 cents, or 0.8%, at $35.80.
On the medical device side, Boston Scientific(BSX Quote) received European regulatory approval for its new Livian implantable defibrillator to treat heart failure. The device is currently under review by the FDA. It monitors a patient's heartbeat, delivering small electrical pulses if necessary. Shares of Boston Scientific were up just 6 cents, or 0.5%, to $11.77. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,309.92 | 1,091.49 | 2,138.44 | 32.31 |
Oil *
77.12
|
|
DOWN
154.48
|
DOWN
19.14
|
DOWN
37.61
|
DOWN
0.48
|
10 Yr
3.23%
SPDR Gold
115.06
|
|
-1.48%
|
-1.72%
|
-1.73%
|
-1.46%
|
Data delayed 20 minutes |
Connect with TheStreet